OpenAI Acquires Orchestra Bio to Expand AI-Assisted Drug Discovery
OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. OpenAI's head of research Mark Chen said the two sides will build on Rosalind, the AI models and tools for life sciences research, to streamline these processes and help new treatments reach patients sooner.
Why read this
SelectedAI score 65
OpenAI's head of research confirmed the acquisition of Orchestra Bio and said it will be integrated into the drug discovery workflow of the life sciences model Rosalind.
Topics
View original postWe’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
View original
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
Body
Excited to welcome Orchestra Bio and @ashokaraj_ to OpenAI as we broaden our work in AI-assisted drug discovery!